CAR T from Creative Biolabs

CAR-T refers to Chimeric Antigen Receptor T-Cell Immunotherapy, which is a modification of the conventional T cell receptor TCR via a chimeric antigen receptor and is generally engineered into a monoclonal antibody antigen-binding domain. In the scFV segment, the modified CAR-T cells can specifically recognize tumor-associated antigens, and are not limited by MHC, so that the targeting, killing activity, and persistence of effector T cells are improved compared with conventional immune cells. CAR-T technology generally selects cytotoxic T lymphocytes (CTLs) for modification because CTLs recognize tumor antigens and release granzymes and perforin to kill tumors.

Researchers at the Stanford University School of Medicine and the National Cancer Institute of the United States completed a study of children and young people with drug-resistant B-cell leukemia and found that the use of a novel gene therapy has alleviated the condition of these patients.

Immunotherapy is a hot topic in recent years. Research on CAR-T cell therapy has attracted many scientists. This year, the first CAR T immunotherapy was also approved for marketing. This approved CAR-T is called CD19 CAR-T, which utilizes genetic modification of patient T cells to target molecules called CD19 on the surface of cancer cells. The FDA has approved it for the treatment of certain types of hematological cancer.

As a leading service provider of immunotherapy, Creative Biolabs recently launched brand new and cpmrehensive CAR T cell development services, which covers the entire manufacturing process to best suit your technical, program and budget requirements, greatly assisting your research, preclinical investigation and clinical stage development.

Immunotherapy is a hot topic in recent years. Research on CAR-T cell therapy has attracted many scientists. This year, the first CAR T immunotherapy was also approved for marketing. This approved CAR-T is called CD19 CAR-T, which utilizes genetic modification of patient T cells to target molecules called CD19 on the surface of cancer cells. The FDA has approved it for the treatment of certain types of hematological cancer.

The currently known side effects include fever, injection-induced pain, etc., but there is no vomiting caused by chemotherapy, Levy said, and if this therapy is approved by the FDA, it will take at least 1 to 2 years.

In the past three years, although cellular immunotherapy has caused a huge sensation in the field of cancer treatment, many investors believe that this may become a revolution in the field of cancer treatment. However, currently, CAR-T with significant therapeutic effect is mainly focused on CD19-targeting products. CD19 is a specific antigen expressed only on the surface of B cells, and it binds to CD19 antigen using CAR-T to eliminate B cells, which only in the hematological malignancy (leukemia, lymphoma, etc.) play a good therapeutic effect. Therefore, to achieve long-term success for CAR-T R&D, two problems must be solved: looking for antigen targets that are highly compatible with CAR-T other than CD19, and gradually shifting the indication of CAR-T from hematological tumors to solid tumors, the large treatment market. There are few targets that can show similar activity with CD19, and it is worth mentioning that CD22 is a malignant tumor of B cells and B cell maturation antigen (BCMA) of multiple myeloma. The former is similar to CD19, and the latter is a kind of antigens expressed in plasma cell antigens. In addition, the problem of solving solid tumors is even more intractable. So far, there is almost no evidence that CAR-T can overcome many problems in solid tumors, but as long as this is a promising market, related CAR T cell development and research will not stop.